Epithelial-mesenchymal transition (EMT) is a developmental program, which is associated with breast cancer progression and metastasis. Here we report that ectopic overexpression of SOX4 in immortalized human mammary epithelial cells is sufficient for acquisition of mesenchymal traits, enhanced cell migration and invasion, along with epithelial stem cell properties that defined by the presence of a CD44 high /CD24 low cell subpopulation. SOX4 positively regulated expression of known EMT inducers, also activating the TGF-ȕ pathway to contribute to EMT. SOX4
Introduction
Breast cancer is the most common cancer in women worldwide (1) . Tumor metastasis is the leading cause of mortality associated with cancer Several developmentally important transcription factors such as Snail, Twist, FOXC1, FOXC2 and LBX1 were reported to act as molecular triggers of the EMT in breast cancer and other cancers (4, 6) . In addition to these transcription factors, an EMT program can also be initiated by several signal pathways, including TGF-ȕ, Wnt, Notch and Hedgehog (7); among them, the TGF-ȕ signaling plays a significant role in contributing to the initiation of EMT during embryonic development and cancer pathogenesis (8) . Recent studies have demonstrated that EMT endows cancer cell with stem cell-like properties and relates to the highly aggressive basal like breast cancer subtype (9, 10) .
SOX4, a member of the C subgroup of SOX (SRY-related HMG box) transcription factor family that are structurally characterized by a highly conserved HMG box domain that directly binds the minor groove of DNA helix, has been implicated in various development processes, such as embryonic cardiac, central nervous system, lymphocyte development and differentiation, through its transcriptional activity (11) (12) (13) (14) (15) (16) . Besides functioning as a transcriptional factor in regulation of development processes, SOX4 has been implicated in cancer progression. Increased SOX4 expression is observed in many human tumors, including medulloblastoma, small cell lung cancer, prostate cancer, and breast cancer (17) (18) (19) (20) (21) . Both TGF-ȕ and Wnt signal pathways have been implicated in cancer progression and EMT (4, 5) . TGF-ȕ has been shown to induce SOX4 expression in glioma-initiating cells and glioblastoma multiforme (22, 23) . SOX4 has been shown to activate the canonical Wnt signal pathway in cancer cells (24, 25) . Therefore, we speculate that SOX4 might play a role in breast cancer progression and aggression through induction of an oncogenic EMT.
In the present study, we demonstrated that SOX4 was able to activate EMT program in epithelial cells, increase the number of CD44 high /CD24 low population and potentiate mammosphere-forming ability. We also demonstrated that in mammary epithelial cells, SOX4 cooperated with the activated oncogenic Ras to endow the cells with the tumorigenicity in vivo.
We further demonstrated that human TNBC has increased SOX4 expression. These data implicate a novel role of SOX4 in inducing EMT in 
Materials and Methods

Cell culture
MCF10A, MDA-MB-231, BT549, NMuMG, MDCK and 293T cell lines were obtained from the ATCC (Manassas, VA), where they were characterized by DNA-Fingerprinting and isozyme detection. Cells were immediately expanded and frozen such that they could be revived every 3 to 4 months. MCF10A cells were cultured as previously described (26) in DMEM/F12 supplemented with 5% horse serum, 20 ng/ml EGF, 0.5 ȝg/ml Hydrocortisone, 100 ng/ml Cholera toxin,10 ȝg/ml insulin and pen/strep.
MDCK and 293T cells were cultured in DMEM containing 10% FBS (Hyclone). NMuMG cells were maintained in DMEM supplemented with 10% FBS and 10 ȝg/ml insulin. MDA-MB-231 cells were cultured in Leibovitz's L-15 medium with 10% FBS at 37°C without CO 2 . BT549 cells were cultured in RPMI-1640 medium supplemented with 10% FBS and 0.023 IU/ml insulin.
Antibodies and reagents
The antibodies and reagents are listed in Supplementary Materials and Methods.
Immunoblotting
Research. 
Plasmids, viral production and infection of target cells
A description of procedures are detailed in Supplementary Materials and
Methods
Human breast tumor specimens and immunohistochemistry
Human breast tumor specimens were obtained from the Second Hospital of Jilin University, China. Tissue samples were fixed in 10% formaldehyde and embedded in paraffin. Sections were cut and stained using a conventional immunohistochemistry procedure. Briefly, the tissue sections were deparaffinized and rehydrated. Antigen retrieval was performed by heating the sample in 10 mM citrate buffer (pH 6.0) at 95°C for 15 min.
Endogenous peroxidase activity was blocked with peroxidase (DAKO), and sections were blocked with 10% goat serum. Sections were incubated with anti-SOX4 antibody (Abcam, 1:50) for 1 h, followed by incubation with secondary antibodies (DAKO) for 30 min. The immunostaining was developed with 3.3'-diaminobenzidine (DAB). Finally, sections were counterstained with hematoxylin.
Transwell migration and invasion assays
Mammosphere formation assays
Mammosphere assays were performed as described elsewhere (27) with minor modifications. Single cells were plated at 10,000 cells/ml on 6-well ultra-low attachment plates (Corning) in serum-free DMEM/F12 supplemented with 20 ng/ml bFGF, 20 ng/ml EGF, 4 ȝg/mL insulin, 4 ȝg/ml heparin, 1 ȝg/ml hydrocortisone, 0.4% BSA and B27. Fresh medium was supplemented every three days. The mammospheres were counted at day 14. 
Xenograft mouse experiments
Luciferase reporter assays
The protocol is described in Supplementary Materials and Methods.
Cell proliferation assays
Cell growth rates were assessed by the MTT assay as described in Supplementary Materials and Methods.
RT-PCR and real-time PCR analysis
Experiments were performed as described in Supplementary Materials and Methods.
Statistical analysis
Data are presented as mean ± SD. The Student's t test (two-tailed) was used to determine statistically the significance of differences between groups. p<0.05 was considered statistically significant. SOX4 expression intensities in human breast cancer samples were analyzed by Ȥ 2 test.
Statistical analysis was performed using the SPSS17.0 software.
Results
Exogenous SOX4 expression induced EMT in human mammary epithelial cells
Research. To investigate the role of SOX4 in EMT, we stably overexpressed SOX4 in the immortalized normal human mammary epithelial cell line MCF10A that lacks endogenous SOX4 expression, by using retroviral infection, as confirmed by immunoblotting (Fig. 1A) and real-time PCR (Supplementary Fig. S1 ). We observed that MCF10A cells transfected with vector retained their cobblestone-like morphology with tight cell-cell adhesion, whereas cells expressing exogenous SOX4 displayed an elongated fibroblast-like morphology with scattered distribution in culture (Fig. 1B) . We then examined both epithelial and mesenchymal markers by immunoblotting ( Fig. 1C) and immunofluorescence ( Together, these results demonstrate that SOX4 is a novel inducer of EMT and it promotes cell migration and invasion in MCF10A cells.
Loss of E-cadherin appears to be a critical event in EMT. We next Fig. S5H ). Thus, our loss-of-function study suggested that the suppression of SOX4 could partially reverse the EMT phenotype of MDA-MB-231 and BT549 cells. Fig. S6C ). These data implicated that SOX4 and H-RasV12 worked synergistically in inducing a more prominent EMT phenotype.
SOX4-mediated EMT generated stem cell-like cells
To further establish whether SOX4 is able to trigger tumorigenesis in vivo, we tested its effect in a xenograft mouse model. We detected no (Fig. 4A-E 
several poor prognostic parameters such as high tumor grade malignancy (P<0.001), negative ER (P=0.014) and negative PR (P=0.001) ( Table 1) .
Moreover, we observed that high level of SOX4 expression was associated with the highly aggressive triple-negative breast cancer (TNBC).
As shown in Fig. 4F, 45 Table S2 ). These observations implicate the potential usefulness of the aberrant high SOX4 expression as a novel prognostic molecular marker for TNBC.
Activation of TGF-ȕ was necessary for SOX4-induced cell motility
Several lines of evidence have implicated the involvement of TGF-ȕ in
Research. EMT process both in embryonic development and breast cancer progression (8, 30) . We next intended to identify whether TGF-ȕ signaling is activated in SOX4-induced EMT. Our real-time PCR revealed an increased expression of TGF-ȕ1 and TGF-ȕ2 mRNAs in SOX4-expressing MCF10A cells (Fig. 5A ). In addition, the level of phosphorylated Smad2 protein, a downstream effector of TGF-ȕ pathway, was significantly increased in SOX4-expressing MCF10A cells (Fig. 5B left) . Moreover, SOX4 silencing efficiently decreased the level of phosphorylated Smad2 and the expression of TGF-ȕ1 and TGF-ȕ2 mRNAs in SOX4-expressing MCF10A cells (Fig. 5C) ; whereas knockdown of SOX4 upregulated E-cadherin expression and partly downregulated N-cadherin expression, presumably due to the residual ectopic SOX4 (Supplementary Fig. S7A ).
Consistent with these changes, we observed some tight cell clusters upon SOX4 silencing (Supplementary Fig. S7B ). Apparently, these experiments pointed to a reinforced TGF-ȕ signaling upon ectopic SOX4 expression in MCF10A cells. To further validate that TGF-ȕ signaling is responsible for the SOX4-induced EMT and the enhanced cell motility, we employed a specific TGF-ȕ receptor kinase inhibitor SB431542 to block the TGF-ȕ signaling in SOX4-expressing MCF10A cells. We found that suppression of TGF-ȕ signaling by the inhibitor reduced Smad2 phosphorylation level and downregulated Vimentin expression (Fig. 5B right) (Fig. 5D and 5E ). These results suggest that the intensified TGF-ȕ signaling induced by SOX4 promotes cell motility, and this partly contributes to EMT.
TGF-ȕ signaling has been shown to be able to induce EMT in many epithelial cells including MCF10A and NMuMG (31, 32) . In addition, recent studies have shown that SOX4 is a direct target gene of TGF-ȕ in glioma-initiating cells and is also responsive to TGF-ȕ in glioblastoma multiforme (22, 23) . Here we showed that SOX4 mRNA was also induced in MCF10A (Fig. 6A and 6B ) and NMuMG ( Supplementary Fig. S8 ) cells, in a dose-and time-dependent manner upon the addition of TGF-ȕ to the cell culture medium. To investigate whether SOX4 is required for TGF-ȕ induced EMT, we knocked down SOX4 expression in MCF10A cells with shRNA and examined their responses to TGF-ȕ1 treatments. MCF10A cells expressing SOX4 shRNA (MCF10A-shSOX4#2) or non-target control shRNA (MCF10A-shCtrl) were treated with TGF-ȕ1. We observed that SOX4 expression was induced 48h after TGF-ȕ1 addition in the MCF10A-shCtrl cells, whereas MCF10A-shSOX4#2 cells exhibited a reduction in the basal expression level of SOX4 as well as in the induction of SOX4 after TGF-ȕ1 stimulation (Fig. 6C) . We also found that TGF-ȕ1 treatments induced EMT in MCF10A-shCtrl cells, but not in MCF10A-shSOX4#2 cells (Fig. 6D) . Consistent with morphological changes, E-cadherin expression was inhibited and N-cadherin expression was increased in MCF10A-shCtrl cells after TGF-ȕ1 treatments. However, under the same conditions E-cadherin and N-cadherin expression were not changed in MCF10A-shSOX4#2 cells (Fig. 6C) . These experiments suggest that SOX4 is also involved in and required for TGF-ȕ induced EMT.
Discussion
Increasing evidence suggests that SOX4 overexpression is associated with several human cancers including brain, lung and breast cancers (17) . 
promoter; rather, it may indirectly activate the ZEB1 promoter through as yet unidentified intermediate factor(s).
More importantly, our data have suggested that SOX4 is also involved in and required for TGF-ȕ induced EMT. We demonstrate in our study that the autocrine TGF-ȕ signaling is activated in SOX4-induced EMT; Fig. S6B ), but these inducers do not function cooperatively with Ras either. These data seem to support the assumption that only the exogenous EMT inducers and activated Ras are able to exert the cooperative effects to promote even more dramatic characteristics of EMT and cancer progression (6, 9, 29, 41) . Our results in this study are in favor of a strong correlation between SOX4 and TNBC, and hence point to the prospect of using SOX4 as a novel biomarker for prognosis and diagnosis of TNBC, as well as a potential molecular therapeutic target for this highly aggressive breast cancer. 
